Search

Carlos Arrecubieta

age ~54

from New York, NY

Carlos Arrecubieta Phones & Addresses

  • 55 Nagle Ave APT 6B, New York, NY 10040

Us Patents

  • Inhibiting Staphylococcus Epidermidis Infections

    view source
  • US Patent:
    20110117099, May 19, 2011
  • Filed:
    Jan 16, 2008
  • Appl. No.:
    12/523425
  • Inventors:
    Carlos Arrecubieta - New York NY, US
    Franklin D. Lowy - Hastings-on-Hudson NY, US
  • Assignee:
    The Trustees of Columbia University in the City of New York - New York NY
  • International Classification:
    A61K 39/40
    C07K 14/31
    A61K 39/085
    C07H 21/04
    A61K 31/7088
    C12N 15/63
    C12N 1/21
    A61K 35/74
    C07K 16/12
    A61P 31/04
  • US Classification:
    4241391, 530350, 4242431, 536 237, 514 44 R, 4353201, 4352523, 424 932, 5303879
  • Abstract:
    The invention relates to peptides, antibodies and nucleic acids that can inhibit infection of a mammalian subject and colonization of a medical device in the mammal.
  • Human Antibodies To Clostridium Difficile Toxins

    view source
  • US Patent:
    20130230531, Sep 5, 2013
  • Filed:
    Mar 1, 2013
  • Appl. No.:
    13/782444
  • Inventors:
    Carlos Arrecubieta - New York NY, US
    Israel Lowy - Dobbs Ferry NY, US
  • Assignee:
    Regeneron Pharmaceuticals, Inc. - Tarrytown NY
  • International Classification:
    C07K 16/12
    A61K 39/40
  • US Classification:
    4241391, 5303895, 4241671, 5303879
  • Abstract:
    The present invention provides fully human antibodies that bind to either toxin A or toxin B of , or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from , thus providing a means of treating the disease and symptoms associated with a infection, including the treatment of diarrhea, or pseudomembranous colitis caused by . The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of . The antibodies of the invention may also be useful for diagnosis of an infection by

Get Report for Carlos Arrecubieta from New York, NY, age ~54
Control profile